34 results
8-K
EX-10.3
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
commensurate with the functions of your role and your knowledge, skills and experience.
You shall exercise your powers in your role as a non-executive director … management and in succession planning;
devote time to developing and refreshing your knowledge and skills;
uphold high standards of integrity
8-K
EX-10.4
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
, diligently and to a standard commensurate with the functions of your role and your knowledge, skills and experience.
You shall exercise your powers in your … and, where necessary, removing senior management and in succession planning;
devote time to developing and refreshing your knowledge and skills;
uphold
8-K
EX-10.2
sskl3j
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
S-4/A
EX-99.4
wdydngodh566vga 40w
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
864tqzym5cl0mxe6r
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.1
t0x7f3
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-99.1
uagbvsagk
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am